Safety Concerns About Saltz Regimen Were Statistical Artifact, ODAC Finds.
AACI: von Eschenbach “Wonderful Choice” For NCI Director, Knows How Centers Work. Cancer Centers Pleased With Bush Choice For NCI.
Campus-Dweller Rabson Finds Comfort In NIH Security.
Endostatin Enters Phase II Trial For Neuroendocrine Tumors.
Siemens To Provide Technology To DxTx For Lung Cancer Detection.
Myriad In Partnership To Market Products.
Computer-Aided Detection Approved For Mammograms.
Trending Stories
- Richard Pazdur left FDA to avoid being part of “the destruction of the American medical system”
- Pediatric cancer five-year survival rate has increased dramatically, AACR says in inaugural Pediatric Cancer Progress Report
- In first NCAB director’s report, Anthony Letai focuses on centralized grant review, budget outlook
- Antonio Wolff, Mikala Egeblad named co-directors of Johns Hopkins Kimmel Cancer Center Breast and Gynecologic Cancer Program
- Pazdur leaves FDA after 25-year career that shaped the agency’s oncology regulations
BIO calls for the end of “constant turmoil,” urges the administration to “right the ship” - Anthony Letai pledges to ensure stability for extramural and intramural cancer science









